Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

Overview

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Full Title of Study: “Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn’s Disease Colitis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2024

Detailed Description

Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group. CD patients whose CDAI >150 were divided into the active CD group.

Interventions

  • Diagnostic Test: serum leucine-rich alpha-2 glycoprotein (LRG) levels
    • Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.

Clinical Trial Outcome Measures

Primary Measures

  • Serum LRG measurement
    • Time Frame: one year
    • Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients whom possible UC or Crohn disease was suspected Exclusion Criteria:

  • other autoimmune diseases – acute or chronic renal failure – chronic heart diseases – liver cirrhosis – cancer – acute or chronic infections – ischemic colitis – infectious colitis

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Showa Inan General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Akira Horiuchi, Chief – Showa Inan General Hospital
  • Overall Contact(s)
    • Akira Horiuchi, MD, 81265822121, horiuchi.akira@sihp.jp

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.